On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15. Eli Lilly’s stock price opened at $84.46 on January 2 and reached $113.83 on November 16, which representing ~35% year-to-date growth.
Eli Lilly’s stock price closed at $113.83 on November 16, which reflects ~54% growth from its 52-week low of $73.69 on February 9. Eli Lilly hit its 52-week high of $116.61 on October 8.
Eli Lilly generated net revenues of $18.1 billion during the first nine months of 2018—compared to $16.7 billion during the same period in 2017, which reflects ~8% YoY (year-over-year) growth.
Eli Lilly reported a net income and diluted EPS of $2.1 billion and $2.03 during the first nine months of 2018—compared to its net income and diluted EPS of $1.5 billion and $1.37 during the same period in 2017, which reflects ~45% and 48% YoY growth.
The company’s revenue growth could boost the iShares Edge MSCI USA Quality Factor ETF’s (QUAL) share prices. Eli Lilly accounts for ~1.83% of QUAL’s total portfolio holdings.
Eli Lilly’s Trulicity, Taltz, Jardiance, Lartruvo, Basaglar, Verzenio, and Cyramza mainly contributed to the company’s revenue growth during the first nine months of 2018. Trulicity, Taltz, and Cyramza generated revenues of $2.3 billion, $630.4 million, and $600.8 million, respectively, during the first nine months, which reflects ~65%, ~63%, and 9% YoY growth.
Eli Lilly’s Jardiance and Lartruvo reported revenues of $465.1 million and $221.2 million, respectively, during the first nine months of 2018, which reflects ~53% and 54% YoY growth. Eli Lilly’s Basaglar and Olumiant’s revenues during the first nine months of 2018 amounted to $569.0 million and $132.5 million, respectively—compared to $278.3 million and $22.8 million during the same period in 2017.
Among the 18 analysts tracking Eli Lilly in November, three recommended a “strong buy,” six recommended a “buy,” and nine recommended a “hold” for Eli Lilly in November.
On November 19, Eli Lilly had a consensus 12-month target price of $113.06, which represents an ~0.68% decline over the next 12 months.